PTC CLINIC
Informace pro odborníky

Odborné publikace PTC nádory jícnu

1. Vítek P., Kubeš J. Co přináší protonová radioterapie nádorů jícnu. Onkologie. 2022:16(5):239-245. Doi: 10.36290/xon.2022.045.
2. Vítek P., Kubeš J., Jiránková K., Vondráček V. Definitivní protonová chemoradioterapie u nádorů krčního jícnu – předběžná analýza výsledků. Onkologie. 2024:18(1):53-58. Doi: 10.36290/xon.2024.011.

Reference, Klinické a dozimetrické studie nádory jícnu

1. www.svod.cz
2. Meredith K.L., Weber J.M., Turaga K.K., Siegel E.M. et al. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann. Surg. Oncol. 2010; 4: 1159-67.
3. Chirieac L.R., Swisher S.G., Ajani J.A., Komaki R.R. et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005; 103:1347-55.
4. Ono T., Wada H., Ishikawa H., Tamamura H. et al. Clinical results of proton beam therapy for esophageal cancer: Multicenter retrspective study in Japan. Cancers 2019; 11:993.
5. Zhang W., Luo Y., Wang X., Han G. et al. Dose-escalated radiotherapy improved survival for esopahgeal cancer aptients with a clinical complete response after stadnard-dose radiotherapy with concurrent chemotherapy. Cancer Management and Research 2018; 10:2675-2682.
6. Akiyama H. et al. Principles of surgical treatment for carcinoma of the esopahagus: Analysis of lymphnode involvement. Ann. Surg. 1981; 194:438.
7. Chen J., Suoyan L., Pan J., Zheng X. et al. The pattern and prevalence of lymphatic spread in thoracic oesophageal squamous cell carcinoma. European Journal of Cardio-thracic Surgery 2009; 36: 480-486.
8. Sharma S. et al. Patterns of lymph-node metastasis in 3-field dissection for carcinoma in the thoracic oesopahgus. Surg. Today 1994; 24:410.
9. Wang J., Wei C., Tucker S.L., Myles B. et al. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2013;86:885-91.
10. Casson A.G. et al. Lymphnode mapping of esophageal cancer. Ann. Thorac. Surg. 1994; 58:1569.
11. www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf
12. Lordick F., Mariette C. Haustermans K., Obermannova R. et al. Oesopahgeal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2016; 27 (Suppl. 5): v60-v67.
13. Minsky B., Pajak T.F., Ginsberg R., Pisansky T.M. et al. INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation Therapy. J. Clin. Oncol. 2002; 20:1167-74.
14. Yamashita H., Okuma K., Wakui R., Kobayashi-Shibata S. et al. Details of recurrence sites after elective nodal irradiation (ENI) using 3D-conformal radiotherapy (3D-CRT) combined with chemotherapy for thoracici esophageal squamaous cell carcinoma – a retrspective analysis Radiother. Oncol. 2011; 98:255-260.
15. Onozawa M., Nihei K., Ishikura S. et al. Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus. Radiother. Oncol. 2009; 92: 266-269.
16. Di Fiore F., Lecleire S., Rigal O. et al. Predictive factors of survival in patients treated with definitive chemoradiotehrapy for squamous cell esophageal carcinoma. World J. Gastroenterol. 2006; 12:4185-4190.
17. Suh Y.G., Lee I.J., Koom W.S. et al. High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer. Jpn. J. Clin. Oncol. 2014; 44:534-540.
18. He L., Allen P.K., Potter A. et al. Re-evaluating the optimal radiation dose for definitive chemoradiotherapy for esopahgeal squamous cell carcinoma. J. Thorac. Oncol. 2014; 9:1398-1405.
19. Zhang W., Luo Y., Wang X., Han G. et al. Dose-escalated radiotherapy improved survival for esophageal cancer patients with a clinical complete response after standard dose radiotherapy with concurrent chemotherapy. Cancer management and Research 2018; 10:2675-2682.
20. Fan C-Y., Su Y-F. Huang W-Y, Chao H-L et al. Definitive radiotherapy dose escalaltion with chemotherapy for treating non-metastatci oesophageal cancer. Scientific reports 2018; 8:12877.
21. Viklund P., Lindblad M., Lu M., Ye W., Johansson J. Risk factors for complications after esophageal cancer resection: a prospective population-based study in Sweden. Ann Surg. 2006 ;243:204-11.
22. Bosch D.J., Muijs C.T., Mul V.E., Beukema J.C. Impact of neoadjuvant chemoradiotherapy on postoperative course after curative-intent transthoracic esophagectomy in esophageal cancer patients. Ann Surg Oncol. 2014; 21:605-11.
23. Shiraishi Y., Fang P., Xu C., Song J. et al. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol. 2018; 128:154-160.
24. Wang J., Wei C., Tucker S.L., et al. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2013; 86:885-91.
25. Van der Werf L., Busweiler L.A.D., van Sandick J.W. et al. Reporting National Outcomes After Esophagectomy and Gastrectomy According to the Esophageal Complications Consensus Group (ECCG). Annals of Surgery 2019 Jan 19. doi: 10.1097/SLA.0000000000003210. [Epub ahead of print].
26. Lee H.K. Vaporciyan A.A., Cox J.D. et al. Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys. 2003; 57:1317-22.
27. Lin S.H., Merrell K.W., Bhooshan N., Correa A.M. Radiation modality use and the icidence of pstoperative complications and legth of hospitalization after trimodality therapy for esophageal cancer: A multiinstitutional analysis. Int. J. Radiat. Oncol. Biol. Phys. 2019; 105; Suppl. 1, Abst. 27, S12.
28. Lin S.H., Hobbs B.,Thall P.,Tidwell R.S. et al. Results of a Phase II Randomized Trial of Proton Beam Therapy vs Intensity Modulated Radiation Therapy in Esophageal Cancer. Int. J. Radiat. Oncol. Biol. Phys. 2019; 105: 680–681.
29. Thomas M., Defraene G., Lambrecht M., Deng W. et al. NTCP model for postoperative complications and one-year mortality after trimodality treatment in oesophageal cancer. Radiother Oncol. 2019;141:33-40.
30. Haj M. N., De Rooij S., Hulshof M. et al. Activities of daily living and quality of life during treatment with neoadjuvant chemoradiotherapy and after surgery in patients with esophageal cancer. J Surg Oncol. 2016;114:684-690.
31. Wang J., Wei C., Myles B., Cox J.D. et al. Radiation Modality is a Strong Predictor for Postoperative. Pulmonary and GI Complications After Trimodality Therapy for Esophageal Cancer. Int. J. Radiat. Oncol. Biol. Phys. 2019; 105; Suppl. 1, Abst. 100, S40.
32. Lin J.B. , Hung L-C. , Cheng C-Y., Chien Y-A et al. Prognostic significance of lung radiation dose in patients with esophageal cancer treated with neoadjuvant chemoradiotherapy Radiat. Oncol. 2019; 14:85.
33. Kato K., Muro K., Minashi K., Ohtsu A. et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int. J. Radiat. Oncol. Biol. Phys. 2011, 81, 684–690.
34. Nishimura Y.,Mitsumori M., Hiraoka M., Koike, R. et al. A randomized phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer: Short-term infusion versus protracted infusion chemotherapy (KROSG0101/JROSG021). Radiother. Oncol. 2009, 92, 260–265.
35. Makishima H., Ishikawa H., Terunuma T., Hashimoto, T. et al. Comparison of adverse e_ects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis. J. Radiat. Res. 2015, 56, 568–576.
36. Hirano Y., Onozawa M, Hojo H. Motegi A. et al. Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma. Radiat. Oncol. 2018, 13: 23.
37. Hayashi K., Fujiwara Y., Nomura M., Kamata M. et al. Predictive factors for pericardial e_usion identified by heart dose-volume histogram analysis in oesophageal cancer patients treated with chemoradiotherapy. Br. J. Radiol. 2015, 88: 20140168.
38. Frandsen J., Boothe D., Gffney D.K.,Wilson B.D. et al. Increased risk of death due to heart disease after radiotherapy for esophageal cancer. J. Gastrointest. Oncol. 2015; 6:516–523.
39. Welsh J., Gomez D., Palmer M.B., Riley B.A. et al. Intensity-modultaed proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: A dosimetric study. Int. J. Radiat. Oncol. Biol. Phys. 2011; 81: 1336 – 1342.
40. Zhang X., Zhao K., Guerrero T.M., McGuire S.E. et al. Four-dimensional computera tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esopahgeal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2008; 72: 278-287.
41. Makishima H., Ishikawa H., Terunuma T., Hashimoto T. et al. Comparison of adverse effects on proton and X-ray chemoradiotehrapy for esophageal cancer using and adaptive dose-volume histogram analysis. Journal of Radiation Research 2015; 56:568-576.
42. Wang J., Wei C., Tucker S.L., Myles B. et al. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2013; 86:885-891.
43. Makishima H., Ishikawa H., Terunuma T., Hashimoto T. et al. Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis. J. Radiat. Res. 2015, 56, 568–576.
44. Mizumoto M., Sugahara S., Nakayama H., Hashii H. et al. Clinical results of proton-beam therapy for locoregionally advanced esophageal cancer. Strahlenther. Onkol. 2010; 186:482-488.
45. Sugahara S., Tokuuye K., Okumura T., Nakahara A. et al. Clinical results of proton beam therapy for cancer of the esophagus. Int. J. Radiat. Oncol. Biol. Phys. 2005; 61:76-84.
46. Mizumoto M., Sugahara S., Okumura T., Hashiomoto M. et al. Hyperfractionated concomitant boost proton beam therapy for esophageal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2011; 81:601-606.
47. Lin S.H., Komaki R., Liao Z., Wei C. et al. Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2012; 83:345-351.
48. Koyama S., Tsujii H. Proton beam therapy with high-dose irradiation for superficial and advanced esophageal carcinomas. Clin. Cancer Res. 2003; 9:3571-7.
49. https://clinicaltrials.gov/ct2/show/NCT03801876